CareDx, Inc (CDNA)
After hours:
| Previous close | 8.07 |
| Open | 7.98 |
| Bid | 8.28 x 100 |
| Ask | 8.36 x 100 |
| Day's range | 7.98 - 8.34 |
| 52-week range | 4.80 - 12.93 |
| Volume | |
| Avg. volume | 896,992 |
| Market cap | 430.279M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.54 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.40 |
Business WireCareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 19, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the "Inducement Option") and 487,804 restricted stock units (the "Inducement RSUs" ) to Jo
ZacksCareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Business WireCareDx Appoints John W. Hanna as its New President and Chief Executive Officer
BRISBANE, Calif., April 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
